Video: Roberto Soto, MD, of Precision Imaging, shows a recent PET imaging case using Amyvid, recently approved for evaluation of Alzheimer's.
Roberto Soto, MD, founder and medical officer of Precision Imaging, shows a recent PET imaging case using Amyvid. The radioactive diagnostic agent Amyvid, or florbetapir, was FDA-approved in April for use in the evaluation of Alzheimer’s disease.
In this case, the patient also had an MRI, as seen in the top row. The studies were fused to show additional information. This is a negative Amyvid case, meaning no amyloid plaque was detected and there was a reduced likelihood the impairment is due to Alzheimer’s.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Enhanced Mobile CT System with High-Resolution Photon-Counting Technology
July 15th 2024Photon-counting CT-optimized features with the OmniTom Elite system include 30 cm field of view scanning, continuous spiral scanning, and an ultra-high-resolution capability of 0.141 mm resolution.